AdaptHealth (AHCO) Q1 2026 earnings review
Top-Line Growth Returns, but Transition Costs Crush the Bottom Line
AdaptHealth finally broke its revenue stagnation, posting 5.4% YoY growth (9.1% organically) driven by the massive new exclusive managed care contract launch. However, as management telegraphed in the prior quarter, this revenue surge came with a heavy toll on profitability. Net Loss more than doubled to $16.0M, Adjusted EBITDA fell 5.3%, and Free Cash Flow turned sharply negative. The company incurred $12.0M in elevated labor expenses to handle the sudden volume influx. Management raised the full-year revenue outlook slightly but kept profit guidance unchanged, signaling confidence that these transition costs will burn off by mid-year.
🐂 Bull Case
Organic growth hit 9.1%, a massive step-up from 1.7% in Q4 2025. This proves the company can successfully onboard industry-record volumes from its new 10-million-member strategic partnership.
A newly completed $1.1 billion refinancing lowers the weighted average cost of debt, pushes out maturities, and provides committed capital to redeem 2028 notes, securing the runway needed to execute the growth plan.
🐻 Bear Case
Adjusted EBITDA margin compressed to 14.8% from 16.4% a year ago. The $12.0M in elevated labor costs highlights the severe operational strain and execution risk inherent in scaling so quickly.
Free Cash Flow fell to negative $27.5M. The new contract requires heavy upfront fixed asset purchases, driving CapEx up significantly and pressuring near-term liquidity.
⚖️ Verdict: ⚪
Neutral. The revenue acceleration is highly encouraging, but the resulting margin compression and cash burn are severe. If management successfully sheds the $12M in transition labor costs by Q2 as promised, the stock will re-rate higher. Until then, it's a 'show me' story.
Key Themes
Elevated Transition Costs Crushing Margins
Decelerating. Adjusted EBITDA margins compressed to 14.8%, down from 19.3% in the prior quarter and 16.4% a year ago. The culprit was clearly identified: $12.0M in elevated labor expenses required to handle the aggressive go-live schedule of the new strategic partnership. While management expects the variable portion to normalize by the end of Q2, this leaves zero room for error in the back half of the year to meet guidance.
Digital Patient Engagement Accelerating
Accelerating. Technological innovation is successfully driving patient self-service. Registered myApp users grew to 412,000, representing a massive 26% sequential jump from 327,300 in Q4 2025. This digital shift is the exact operational leverage AdaptHealth needs to eventually offset the current spike in manual labor costs.
Capital Intensity Sinks Free Cash Flow
Reversing. Free Cash Flow dropped to negative $27.5M from slightly below zero (-$0.1M) a year ago. The core issue is not operating cash (which remained stable at $93.7M), but the massive capital expenditure required to fund the new contract's equipment needs. Purchases of equipment and fixed assets surged to $121.2M compared to $95.6M in Q1 2025.
Macro Tailwinds: Debt Refinancing Secures the Runway
Stable. In an environment where interest expense has historically eaten into profitability (costing $25.6M this quarter), AdaptHealth completed a crucial $1.1B refinancing in April 2026. This lowers the weighted average cost of debt and dramatically reduces near-term amortization. Most importantly, it guarantees the capital needed to redeem high-yield 2028 notes, removing a major balance sheet overhang.
Portfolio Pruning Complete
The company completed the disposition of its remaining custom rehabilitation assets in April 2026. Following the sales of incontinence and infusion businesses in 2025, the portfolio is now cleanly concentrated entirely on core, scalable units: Sleep, Respiratory, Diabetes, and Wellness at Home.
Other KPIs
Accelerating. This is a dramatic improvement from the 1.7% organic growth recorded in both Q4 and FY 2025. It proves that despite portfolio divestitures dragging down reported revenue in prior quarters, the underlying core business paired with the new contract wins is generating real, robust volume.
Decelerating. The net loss more than doubled compared to a $7.2 million loss in Q1 2025. While operating income remained positive at $5.5M, it was nearly wiped out by the $12M in transition labor costs, leaving it unable to cover the $25.6M in quarterly interest expense.
Guidance
Accelerating. Management raised the full-year guidance by $10 million. The midpoint ($3.485B) implies approximately 7.4% YoY growth compared to FY 2025 ($3.24B). This reflects confidence that the massive onboarding effort is translating securely into recurring top-line dollars.
Accelerating strictly in the back half. Guidance was maintained, implying ~14% YoY growth over 2025's $616.7M. However, because Q1 only delivered $121.2M, the company must average roughly $194M per quarter for the rest of the year to hit the midpoint. This assumes a flawless roll-off of the $12M transition costs.
Reversing. Maintained from prior outlook. Given Q1 started in a $27.5M hole, the remaining three quarters must generate roughly $227M in aggregate FCF to hit the midpoint. This implies CapEx will fall significantly from Q1's $121M peak as initial equipment outlays for the new contract conclude.
Key Questions
Labor Cost Normalization Path
You noted the $12 million in elevated labor costs will 'normalize by the end of the second quarter.' Is this a cliff-drop at the end of June, or a linear phase-out? How much residual permanent wage inflation remains in the run-rate?
CapEx Trajectory
With $121 million spent on CapEx in Q1 and a maintained FCF target, what is the expected quarterly step-down in CapEx for the remainder of the year now that the new contract has launched?
Segment Performance Check
While you noted broad-based organic growth, the Diabetes segment was struggling throughout early 2025. Can you break out whether Diabetes has finally returned to positive YoY growth, or if Sleep and Respiratory are masking ongoing weakness?